Form 4: RenovoRx CMO Granted Over 600,000 Stock Options

RenovoRx, Inc. has granted Chief Medical Officer Ramtin Agah options to purchase 621,727 shares at an exercise price of $0.98.

Summary

• Ramtin Agah, the Chief Medical Officer and Director of RenovoRx, Inc., was granted 621,727 stock options on April 3, 2026.
• The grant is split into 319,073 incentive stock options and 302,654 non-qualified stock options.
• The exercise price for these options is set at $0.98 per share.
• Vesting occurs monthly at a rate of 1/48 per month, having commenced retroactively on January 1, 2026.
• The options will become fully vested by January 1, 2030, and are set to expire on April 3, 2036.
• A specific condition requires an effective registration statement covering the underlying shares before the options become exercisable.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it secures key leadership for the next four years, though it introduces modest future dilution.

Positives

• Strong alignment of management interests with long-term shareholder value through a four-year vesting schedule.
• Retention of the Chief Medical Officer through at least 2030 via equity incentives.
• The exercise price of $0.98 establishes a clear baseline for management's performance expectations.

Negatives

• Potential future dilution of 621,727 shares for existing common stockholders.
• The options are currently not exercisable, pending the filing and effectiveness of a registration statement.

Risks

• Dilution risk to existing shareholders upon the exercise of these derivative securities.
• Regulatory risk regarding the timing and approval of the required registration statement to make the options exercisable.

Future Outlook

The grant indicates a long-term commitment to the company's clinical and strategic goals through 2030, contingent on the company maintaining regulatory compliance for share registration.

Management Comments

• The Compensation Committee of the Board of Directors approved the grant of stock options to the Chief Medical Officer.

Industry Context

StockSavvy.ai notes that clinical-stage biotechnology companies heavily utilize equity-based compensation to retain specialized medical leadership during multi-year drug development and trial cycles.

Comparison to Industry Standards

• A four-year vesting period is a standard industry benchmark for executive retention in the biotech sector.
• Monthly vesting without an initial one-year cliff is slightly more favorable to the executive than typical Silicon Valley standards.
• The requirement for an effective registration statement before exercise is a common safeguard for companies managing their public float and regulatory filings.

Corporate Governance

Related Party Transactions

• Grant of 621,727 stock options to Ramtin Agah, who serves as both a Director and Chief Medical Officer.

Stakeholder Impact

• Shareholders: Face potential dilution of approximately 621,727 shares in the future.
• Management: Receives significant long-term incentive tied to the company's stock price performance.

Next Steps

• The company must ensure an effective registration statement is in place for the shares to be exercisable.
• Continued monthly vesting of the options through January 2030.

Key Dates

Recommendation

This is a routine executive compensation filing. While it shows management commitment, it does not provide new information regarding clinical trials or revenue that would change a fundamental investment thesis.

Keywords

RenovoRx, RNXT, Stock Options, Executive Compensation, Ramtin Agah, Chief Medical Officer, Insider Transaction, Equity Grant